Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomasResearch in context
Background: Olaratumab (LY3012207/IMC-3G3/Lartruvo™) is a fully human monoclonal antibody specific for platelet-derived growth factor receptor alpha (PDGFRα). Phase Ib/II trial results of olaratumab plus doxorubicin in adult patients with advanced soft tissue sarcoma (STS) supported accelerated FDA...
Main Authors: | Erin J. Song, Kathleen A. Ashcraft, Caitlin D. Lowery, Yvonne M. Mowery, Lixia Luo, Yan Ma, Lorraine Da Silva Campos, Diana M. Cardona, Louis Stancato, David G. Kirsch |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-02-01
|
Series: | EBioMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396419300532 |
Similar Items
-
Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma
by: Jianguo Huang, et al.
Published: (2017-07-01) -
Role of detrusor PDGFRα+ cells in mouse model of cyclophosphamide-induced detrusor overactivity
by: Haeyeong Lee, et al.
Published: (2022-03-01) -
Contribution of PDGFRα-positive cells in maintenance and injury responses in mouse large vessels
by: Kenichi Kimura, et al.
Published: (2021-04-01) -
MR histology reveals tissue features beneath heterogeneous MRI signal in genetically engineered mouse models of sarcoma
by: Stephanie J. Blocker, et al.
Published: (2024-05-01) -
Mitochondrial DNA and Functional Investigations into the Radiosensitivity of Four Mouse Strains
by: Steven B. Zhang, et al.
Published: (2014-01-01)